Neurogene Inc Share Price Today: Live Updates & Key Insights

Neurogene Inc share price today is $19.14, up -0.73%. The stock opened at $18.72 against the previous close of $19.19, with an intraday high of $19.79 and low of $18.53.

Neurogene Inc Share Price Chart

Neurogene Inc

us-stock
To Invest in {{usstockname}}
us-stock

Neurogene Inc Share Price Performance

$19.14 -0.0073(-0.73%) NGNE at 23 Mar 2026 02:27 PM Biotechnology
Lowest Today 18.53
Highest Today 19.79
Today’s Open 18.72
Prev. Close 19.19
52 Week High 37.27
52 Week Low 6.88
Day’s Range: Low 18.53 High 19.79
52-Week Range: Low 6.88 High 37.27
1 day return -
1 Week return -11.63
1 month return +4.07
3 month return -8.33
6 month return +12.78
1 year return +36.51
3 year return +48.39
5 year return -92.12
10 year return -

Neurogene Inc Institutional Holdings

Neurogene Inc Market Status

Strong Buy: 4

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Neurogene Inc Fundamentals

Market Cap 295.08 M

PB Ratio 1.1194

PE Ratio 0.0

Enterprise Value 43.11 M

Total Assets 335.73 M

Volume 300286

Neurogene Inc Company Financials

Annual Revenue FY23:0 0.0M, FY23:0 0.0M

Annual Profit FY23:null 0.0M, FY23:null 0.0M

Annual Net worth FY23:-36317000 -36.3M, FY23:-55189000 -55.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:925000 0.9M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-812000 -0.8M, Q1/2025:-762000 -0.8M, Q3/2024:null 0.0M, Q2/2024:-14819000 -14.8M

Quarterly Net worth Q3/2025:-20953000 -21.0M, Q2/2025:-22016000 -22.0M, Q1/2025:-22647000 -22.6M, Q3/2024:-20217000 -20.2M, Q2/2024:-18492000 -18.5M

About Neurogene Inc & investment objective

Company Information Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Organisation Biotechnology

Employees 107

Industry Biotechnology

CEO Dr. Rachel L. McMinn Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Neurogene Inc FAQs

What is the share price of Neurogene Inc today?

The current share price of Neurogene Inc is $19.14.

Can I buy Neurogene Inc shares in India?

Yes, Indian investors can buy Neurogene Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Neurogene Inc shares in India?

You can easily invest in Neurogene Inc shares from India by:

Can I buy fractional shares of Neurogene Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Neurogene Inc?

Neurogene Inc has a market cap of $295.08 M.

In which sector does Neurogene Inc belong?

Neurogene Inc operates in the Biotechnology sector.

What documents are required to invest in Neurogene Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Neurogene Inc?

The PE ratio of Neurogene Inc is N/A and the PB ratio is 1.12.